135 253

Cited 8 times in

Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments

DC Field Value Language
dc.contributor.author김중선-
dc.date.accessioned2021-09-29T02:26:19Z-
dc.date.available2021-09-29T02:26:19Z-
dc.date.issued2020-06-
dc.identifier.issn2093-596X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184894-
dc.description.abstractBackground: This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density lipoprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs). Methods: In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified according to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed. Results: Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. Investigators' assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achievement rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the highest permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respectively. Physician satisfaction with patients' LDL-C levels was the primary reason for non-intensification of statin therapy. Conclusion: Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Endocrine Society-
dc.relation.isPartOfEndocrinology and Metabolism(대한내분비학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBiomarkers / blood*-
dc.subject.MESHCholesterol, LDL / blood*-
dc.subject.MESHCross-Sectional Studies-
dc.subject.MESHDyslipidemias / blood-
dc.subject.MESHDyslipidemias / drug therapy*-
dc.subject.MESHDyslipidemias / epidemiology-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPractice Guidelines as Topic / standards*-
dc.subject.MESHPrognosis-
dc.subject.MESHRepublic of Korea / epidemiology-
dc.subject.MESHRisk Assessment / methods*-
dc.titleAchievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYe Seul Yang-
dc.contributor.googleauthorSeo Young Lee-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorKyung Mook Choi-
dc.contributor.googleauthorKang Wook Lee-
dc.contributor.googleauthorSang-Chol Lee-
dc.contributor.googleauthorJung Rae Cho-
dc.contributor.googleauthorSeung-Jin Oh-
dc.contributor.googleauthorJi-Hyun Kim-
dc.contributor.googleauthorSung Hee Choi-
dc.identifier.doi10.3803/EnM.2020.35.2.367-
dc.contributor.localIdA00961-
dc.relation.journalcodeJ00773-
dc.identifier.eissn2093-5978-
dc.identifier.pmid32615721-
dc.subject.keywordCholesterol, LDL-
dc.subject.keywordHydroxymethylglutaryl-CoA reductase inhibitors-
dc.subject.keywordKorea-
dc.subject.keywordPractice guideline-
dc.subject.keywordRisk assessment-
dc.subject.keywordDyslipidemias-
dc.contributor.alternativeNameKim, Jung Sun-
dc.contributor.affiliatedAuthor김중선-
dc.citation.volume35-
dc.citation.number2-
dc.citation.startPage367-
dc.citation.endPage376-
dc.identifier.bibliographicCitationEndocrinology and Metabolism (대한내분비학회지), Vol.35(2) : 367-376, 2020-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.